Clinical Trial: Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompr

Brief Summary: To evaluate and compare two AmBisome dosing regimens for the initial treatment of invasive aspergillosis and other filamentous fungal infections diagnosed by modified EORTC criteria in immunocompromised patients, as determined by overall response rates at end of course of treatment.

Detailed Summary:

To evaluate and compare two AmBisome dosing regimens for the initial treatment of invasive aspergillosis and other filamentous fungal infections diagnosed by modified EORTC criteria in immunocompromised patients, as determined by overall response rates at end of course of treatment.

Determine and compare the following parameters for the two treatment arms:

  • Safety and tolerability
  • Survival rates and the rates of infection relapse at 4 weeks Post Treatment.
  • Survival rate at 12 weeks after study entry.
  • Time to favorable overall response and time to End of Treatment for patients with favorable overall response.
  • Cumulative dose of study drug given through End of Treatment.

Sponsor: Gilead Sciences

Current Primary Outcome: Evaluate two regimens determined by overall response rates at end of tx.

Original Primary Outcome: Same as current

Current Secondary Outcome: Compare Safety/tolerability; survival rates/rates of infection relapse at 4 wks post tx; survival rate at 12 wks after study entry; TOVR; time to end of tx for patients w/favorable overall response;cumulative dose

Original Secondary Outcome: Same as current

Information By: Gilead Sciences

Dates:
Date Received: September 7, 2005
Date Started: April 2003
Date Completion: January 2005
Last Updated: November 17, 2005
Last Verified: September 2005